EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Fibrotic–Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges

Panagiota Tsiri iD, Marousa Kouvela iD, Ourania Papaioannou iD, Vasilina Sotiropoulou, Matthaios Katsaras iD, Nikolaos Syrigos iD, Fotios Sampsonas iD, Argyrios Tzouvelekis

Life · 09.02.2026 · 16 (2) · 295

DOI: 10.3390/life16020295 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 09.02.2026. Verfasst von Panagiota Tsiri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis represents a chronic, progressive, lethal lung disease of various etiologies exerting a dramatic impact on patients’ survival and quality of life. Its increasing prevalence and high mortality rates indicate the importance of early diagnosis and management involving the assessment of specific comorbidities, such as lung cancer. Emerging evidence suggests that in the context of IPF, lung scarring may be a potential risk factor for lung cancer development. Both disease entities present pathogenic commonalities including genetic and epigenetic markers, signaling pathways and cell transformation obtaining mesenchymal phenotypes. Beyond understanding disease pathogenesis, anti-cancer drugs such as nintedanib have been successfully used to treat patients with IPF. Additionally, a therapeutic approach that includes a mix of various pleiotropic anti-fibrotic agents is currently being developed for IPF treatment. Currently, there is no consensus on the application of therapeutic algorithms in concurrent pulmonary fibrosis and lung tumors. This review summarizes the current state of knowledge on common cellular and molecular pathogenetic mechanisms of IPF and lung cancer and highlights potential therapeutic targets with fruitful results.

Schlagwörter

Stichwörter der Autor:innen

fibrosis–cancer continuumidiopathic pulmonary fibrosislung cancerpathogenesistherapeutic targets

Autor:innen und Institutionen

  • Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece.
  • Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT 06511, USA.

ORCID-Profile: Panagiota Tsiri, Marousa Kouvela, Ourania Papaioannou, Matthaios Katsaras, Nikolaos Syrigos, Fotios Sampsonas

Zitieren

APA

Tsiri, P., Kouvela, M., Papaioannou, O., Sotiropoulou, V., Katsaras, M., Syrigos, N., Sampsonas, F., & Tzouvelekis, A. (2026). The Fibrotic–Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges. Life, 16(2), 295. https://doi.org/10.3390/life16020295

Vancouver

Tsiri P, Kouvela M, Papaioannou O, Sotiropoulou V, Katsaras M, Syrigos N, et al. The Fibrotic–Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges. Life. 2026;16(2):295. doi:10.3390/life16020295

BibTeX
@article{Tsiri2026,
  author = {Tsiri, Panagiota and Kouvela, Marousa and Papaioannou, Ourania and Sotiropoulou, Vasilina and Katsaras, Matthaios and Syrigos, Nikolaos and Sampsonas, Fotios and Tzouvelekis, Argyrios},
  title = {The Fibrotic–Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {295},
  doi = {10.3390/life16020295}
}
Kostenlos starten →